The INADcure Foundation, is the only U.S. based nonprofit dedicated exclusively to the INAD community. The Foundation’s mission is to support the development of treatments, including a cure, for Infantile Neuroaxonal Dystrophy (INAD), a lysosomal storage disorder and other forms of PLA2G6-related neurodegeneration (PLAN). PLA2G6-related neurodegeneration (PLAN) is an umbrella term of three diseases caused by PLA2G6 loss. – Infantile Neuroaxonal Dystrophy (INAD) is typically recognized in early childhood between the ages of 6 months and 2 years. A common pattern in young children is loss of previously acquired skills, mental and physical ability and progression of the disease over time. – Atypical or Juvenile Neuroaxonal Dystrophy (aNAD) affects children at around age 4. The symptoms of individuals with aNAD are fairly stable during their early childhood but start declining between the ages of 7 and 12. – A third form affects young adults who develop dystonia-parkinsonism. There is currently no cure for these diseases. We are actively forging partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new and pending treatments. In collaboration with our scientific advisors, we identify the most promising INAD research projects for partnership and funding. We work tirelessly in our efforts to fund the research that we hope will eradicate INAD, so that not one more child has to suffer from this devastating disease.